| Zeit | Aktuelle Nachrichten
Sprache: | | Leser | Medien |
|---|
| 15.05. | Sucampo to be Added to NASDAQ Biotechnology Index | | - | Benzinga.com |
| 14.05. | Stock Investors Bid Up Shares of Sucampo Pharmaceuticals, Up 5.3% | | - | SmarTrend |
| 09.05. | Sucampo's Stock Could Reach $12, Says Maxim's Senior Vice President | | - | Seeking Alpha |
| 08.05. | Sucampo's CEO Discusses Q1 2013 Results - Earnings Call Transcript | | - | Seeking Alpha |
| 07.05. | Sucampo Pharmaceuticals, Inc. - 8-K, Current Report | | - | SEC Filings |
| 24.04. | Sucampo Pharmaceuticals has the Best Relative Performance in the Healthcare Sector | | 1 | SmarTrend |
| 23.04. | Sucampo Pharmaceuticals Rising on Above-Average Volume, Consistent With Trend | | - | SmarTrend |
| 23.04. | Sucampo Wins Approval for Expanded Use of Amitiza in U.S. | | - | Bloomberg |
| 23.04. | Sucampo Pharma Says FDA Approved SNDA for AMITIZA | | - | Benzinga.com |
| 23.04. | Sucampo Pharmaceuticals Announces FDA Approves Supplemental for AMITIZA | | - | Benzinga.com |
| 23.04. | Sucampo Pharma (SCMP) sNDA for AMITIZA Receives FDA Approval | | - | StreetInsider.com |
| 18.04. | Uptrend Call Working As Sucampo Pharmaceuticals Stock Rises 22.1% | | - | SmarTrend |
| 15.04. | Sucampo Pharmaceuticals, Inc. - 8-K, Departure of Directors or Certain Officers; Election ... | | - | SEC Filings |
| 04.04. | Strength In Sucampo Heading Into FDA Decision And Analyst Activity | | 3 | Seeking Alpha |
| 04.04. | 21.2% Return Seen to Date on SmarTrend Sucampo Pharmaceuticals Call | | - | SmarTrend |
| 20.03. | Sucampo Should See Revenue From 3 Continents By Year-End | | 2 | Seeking Alpha |
| 19.03. | Shares of Sucampo Pharmaceuticals Receive a Boost, Up 5.6% | | - | SmarTrend |
| 14.03. | Stock Investors Bid Up Shares of Sucampo Pharmaceuticals, Up 3.6% | | 1 | SmarTrend |
| 14.03. | Sucampo Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript | | - | Seeking Alpha |
| 20.02. | Sucampo Announces RESCULA is Now Available by Prescription Across the US | | 2 | Benzinga.com |
